Immuneering Corporation

NASDAQ (USD): Immuneering Corporation (IMRX)

Last Price

2.19

Today's Change

-0.03 (1.35%)

Day's Change

2.12 - 2.26

Trading Volume

420,282

Overview

Market Cap

64 Million

Shares Outstanding

29 Million

Avg Volume

6,302,670

Avg Price (50 Days)

1.72

Avg Price (200 Days)

2.94

PE Ratio

-1.15

EPS

-1.90

Earnings Announcement

07-Nov-2024

Previous Close

2.22

Open

2.22

Day's Range

2.12 - 2.2597

Year Range

1.0 - 8.89

Trading Volume

420,282

Price Change Highlight

1 Day Change

-1.35%

5 Day Change

-12.40%

1 Month Change

53.15%

3 Month Change

76.61%

6 Month Change

4.29%

Ytd Change

-70.08%

1 Year Change

-64.93%

3 Year Change

-89.92%

5 Year Change

-87.55%

10 Year Change

-87.55%

Max Change

-87.55%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment